Psilocybin With Intracranial Neural Sensing
Enrolling by invitationPhase 1NCT06919640
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is an open-label, single-arm, pilot study exploring the neural, sensory, and cognitive effects of a single, medium dose of psilocybin in patients with chronic pain who already have implanted sensing-capable deep brain stimulation (DBS) devices. Outcomes include multi-site neural recording from previously placed ambulatory sensing-capable DBS devices, quantitative sensory and cognitive testing, and self-reports of pain. We hypothesize that psilocybin will change functional connectivity, decrease clinical and task-based pain reports, and improve cognitive functions.
Study details
- Official title
- Psilocybin With Intracranial Neural Sensing
- Conditions
- Interventions
- Sponsor
- Joshua Woolley, MD, PhD
- Organization
- University of California, San Francisco
- Start date
- 2025-06-01
- Primary completion
- 2028-04-30
- Sex
- All
- Age range
- from 21 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Currently implanted chronic brain sensing device (such as RC+S or Percept) * Not currently enrolled in another trial * Ability to speak and read English * Able to attend all in-person and virtual visits * No changes in medication or major surgical procedures anticipated for the trial * Able to identify someone to accompany from the research unit at the end of drug administration day or agreement to have a study team member accompany them from the research unit Exclusion Criteria: * A health condition that makes this study unsafe or unfeasible, determined by study physicians * Use of medication, vitamins, or supplements and unwilling or unable to discontinue medications that have problematic interactions with psilocybin * Adulthood epilepsy or other seizure disorder * Require supplemental oxygen * Medical finding or diagnosis that would make participation in this trial unsafe
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06919640